First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar

Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092522. doi: 10.1128/aac.00925-22. Epub 2022 Nov 7.

Authors

Aye Su Mon¹, Phyu Win Ei¹, Mi Mi Htwe¹, Myat Htut Nyunt¹, Su Mon Win¹, Wint Wint Nyunt², Zaw Myint³, Wah Wah Aung¹

Affiliations

¹ Advanced Molecular Research Centre, Department of Medical Research, Yangon, Myanmar.
² National TB Reference Laboratory, Aung San, Yangon, Myanmar.
³ National Tuberculosis Program (Yangon Branch), Department of Public Health, Yangon, Myanmar.

No abstract available

Keywords: I491F; Myanmar; Mycobacterium tuberculosis; rifampin resistance.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibiotics, Antitubercular* / pharmacology
Antitubercular Agents / pharmacology
Bacterial Proteins / genetics
DNA-Directed RNA Polymerases / genetics
Drug Resistance, Bacterial / genetics
Mutation
Myanmar
Mycobacterium tuberculosis*

Substances

Antitubercular Agents
DNA-Directed RNA Polymerases
Bacterial Proteins
Antibiotics, Antitubercular